Résistances Thérapeutiques du Cancer de la Prostate

Domaines scientifiques déclarés au RNSR

Mots-clés des publications HAL repérées

Publications HAL récentes repérées

• Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial · 2025

  Résumé de la publication : Background and objective: The CABASTY study showed that more frequent administration of a lower dose of cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without compromising efficacy. Here, we investigated the impact of a biweekly CBZ schedule…

• Enrichment and characterization of muscle extracellular vesicles (EVs) during Trichinella spiralis infection in mice · 2024

  Résumé de la publication : During the muscle invasion by Trichinella spiralis newborn larvae (NBL), the transformation of muscle cells to nurse cells is still not understood, in particular the molecular interplays between host and parasite remains not identified. The emerging role of extracellular vesicles (EVs) in…

• Antimicrobial and anticancer activities of diazenyl compounds · 2024

  Résumé de la publication : Three heterocyclic diazenyl compounds were synthesized by diazotization of 3-aminopyridine and aniline, followed by coupling with 8-aminoquinoleine, morpholine, 1,2,3,4-tetrahydroquinoleine, respectively. The obtained azo compounds are brown to yellow in color and were characterized by various methods such as NMR and X-rays. The…

• Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group · 2023

  Résumé de la publication : Introduction Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome, the most common histological subtype of UrC is adenocarcinoma. UrC develops from an embryonic remnant, and is frequently diagnosed…

• Genomic Prostate Score: A New Tool to Assess Prognosis and Optimize Radiation Therapy Volumes and ADT in Intermediate-Risk Prostate Cancer · 2023

  Résumé de la publication : Genomic classifiers such as the Genomic Prostate Score (GPS) could help to personalize treatment for men with intermediate-risk prostate cancer (I-PCa). In this study, we aimed to evaluate the ability of the GPS to change therapeutic decision making in I-PCa. Only patients…